Therapy of the Murine Plasmacytoma MOPC 104E: Role of the Immune Response2
- 1 September 1978
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 61 (3) , 897-903
- https://doi.org/10.1093/jnci/61.3.897
Abstract
The murine plasmacytoma MOPC 104E was susceptible to cytotoxic therapy in female inbred BALB/c mice. Palpable subcutaneous tumors (0.6–1.2×108 cells) could be cured with a single administration of cyclophosphamide (5–250 mg/kg) or localized irradiation (800–2,400 R). Clonogenic assay showed that, following minimal curative doses of cyclophosphamide or radiation, 0.5–1.5×106 tumor cells should remain viable. Control animals succumbed to progressive, invariably lethal tumor growth after they were given sc injections of 2–3×103 tumor cells. Minimal doses of cyclophosphamide, which were curative in control tumor-bearing animals, were ineffective in treating tumor-bearing animals immunosuppressed by 450 R whole-body irradiation. Subsequent experiments measured the ability of animals cured of the murine plasmacytoma to reject secondary challenge with the same tumor. These experiments demonstrated and partially quantitated the substantial role of the immune response in effecting tumor cure following radiotherapy or chemotherapy.Keywords
This publication has 5 references indexed in Scilit:
- Immunity Against MOPC 104E Plasmacytoma: Effects of Tumor Size and Time Post Therapy on In Vivo Tumor Immunity 2JNCI Journal of the National Cancer Institute, 1978
- Immunostimulation of the Lymphodependent Phase of Neoplastic GrowthJNCI Journal of the National Cancer Institute, 1977
- Circulating Tumor Cells in Murine Myeloma2JNCI Journal of the National Cancer Institute, 1977
- Host immune potentiation of drug responses to a murine mammary adenocarcinomaInternational Journal of Cancer, 1976
- A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS1949